Skip to content
Clinical Trials – home

Hospital Universitario De Salamanca

Verified siteinfo

Spain Paseo De San Vicente 58-182, 37007 Salamanca, Spain

  • 161 trials recruiting
  • Plasma cell myeloma · Myelodysplastic syndrome · Plasma cell myeloma refractory
  • Adults and children

About Specializations

Hospital Universitario De Salamanca in Salamanca, Spain specialises in clinical trials of conditions such as Plasma cell myeloma, Myelodysplastic syndrome, Plasma cell myeloma refractory, Myelofibrosis, and other specialisations. This site conducts important research.

Main research areas of the site

Hematology Research at Hospital Universitario De Salamanca

Clinical research at Hospital Universitario De Salamanca focuses on Hemic and Lymphatic Diseases, with a strong emphasis on myelodysplastic syndrome in people with IPSS-R low- or intermediate-risk disease. The studies are designed to better understand treatment benefit and safety in a common blood disorder seen in the hematology setting.

  • Evaluating a new oral azacitidine approach for myelodysplastic syndrome
  • Comparing treatment effectiveness against best supportive care
  • Assessing safety, response, and overall clinical value of a potential new therapy

This work aims to improve care for patients with lower-risk myelodysplastic syndrome by identifying more effective and practical treatment options.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Paseo De San Vicente 58-18237007 SalamancaSpain
Recruiting now
161 trials
Conditions studied
206
Partner status
Verified site

More sites in SalamancaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

447 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimeticone
  • Sponsor:Novartis Pharma AG

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Epcoritamab for Patients with Relapsed or Refractory Large B Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Fundacion Geltamo

Study of Atezolizumab, Paclitaxel, and Carboplatin for Patients with Stage IIIA and IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion GECP
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.